Ifenprodil

DRUG2 trials

Sponsors

Algernon Pharmaceuticals, Assistance Publique - Hôpitaux de Paris

Conditions

Idiopathic Pulmonary FibrosisMultiple SclerosisRemitting Relapsing Multiple Sclerosis

Phase 2

Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough

CompletedNCT04318704

Algernon PharmaceuticalsIdiopathic Pulmonary Fibrosis

Start: 2020-07-29End: 2022-05-10Updated: 2022-07-19

Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis

Not yet recruitingNCT06330077

Assistance Publique - Hôpitaux de ParisMultiple Sclerosis, Remitting Relapsing Multiple Sclerosis

Start: 2024-03-31End: 2027-06-30Target: 60Updated: 2024-03-26